Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011
Date:10/31/2011

NANJING, China, Oct. 31, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2011 on Monday, November 14, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Monday, November 14 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:United States toll-free:+1.866.519.4004United States toll:

+1.718.354.1231China Domestic:

800.819.0121 China Domestic mobile:

400.620.8038 Hong Kong:

+852.2475.0994Please ask to be connected to Q3 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 21357022.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:
:

+1.866.214.5335United States toll:

+1.718.354.1232The passcode for replay participants is 21357022. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Yehong Zhang

Cindy ZhengPresident

Brunswick GroupSimcere Pharmaceutical GroupTel: +1-212-333-3810Tel: +86-25-8556-6666 ext. 88In Beijing:In Hong Kong:Yue Yu

Joseph Lo Chi-LunBrunswick Group

Brunswick GroupTel: +86-10-5960-8600

Tel: +852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simceres Iremod Receives SFDA New Drug Approval
2. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
4. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
5. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
6. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
7. Simcere Announces Recent Progress of Qiangkes Registration
8. Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
11. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, ... clinical data on the Company,s lead investigational immuno-oncology drug ... co-sponsored by the American Society of Clinical Oncology (ASCO), ... Francisco, CA. "AM0010 induces ... CD8 + T cells in the blood and ...
(Date:1/20/2017)... DUBLIN , Jan 20, 2017 ... Laboratory Testing Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte ... Panel), By End-use, And Segment Forecasts, 2013 - 2024" report ... ... USD 198.5 billion by 2024 Introduction of innovative solutions ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... report to their offering. ... This research service on the global pharmaceutical stability ... a snapshot of the key participants in the market. ... 2016 to 2020. The market is expected to grow at a ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... ... Valentine’s Day is a time when many people celebrate romance and love by giving cards, ... for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day ... $200 and get $50 free. , “A lot of people just buy the more ...
(Date:1/22/2017)... Aliso Viejo, California (PRWEB) , ... January 22, 2017 , ... ... in Photo Cloud to create a beautiful 3D slideshow with complete ease," said Christina ... from the Generators browser to place in the FCPX timeline. Presets include ...
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that distributes ... to the United States as part of its presence to expand its market reach. ... to reduce the productions of nasty toxins as a result of drinking alcohol, eliminating ...
(Date:1/21/2017)... ... 2017 , ... Phytocéane invites you to take an exotic journey ... world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian archipelago ... moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse the body ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... opening of its new medical office in Petaluma, located at 167 Lynch Creek ... room, access to SRO sports medicine and rehabilitation services and on-site ...
Breaking Medicine News(10 mins):